Aptamer-based ATP-responsive delivery systems for cancer diagnosis and treatment

Sameiyan, Elham; Bagheri, Elnaz; Dehghani, Shahrzad; Ramezani, Mohammad; Alibolandi, Mona; Abnous, Khalil; Taghdisi, Seyed Mohammad

doi:10.1016/j.actbio.2020.12.057

Cited by 49 publications

(34 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[120] In comparison with ATP levels in normal cells (2537 × 10 −6 ± 1217 × 10 −6 m), cancer cells exhibited a 1.2-fold higher ATP level (3134 × 10 −6 ± 2135 × 10 −6 m) due to their faster metabolic processes, excess glycolysis, and fast proliferation and growth. [121] It should be noted that mitochondria exhibited the high ATP level of 8.0 × 10 −3 ± 2.6 × 10 −3 m while the ATP level in cytoplasm was measured to be 3.3 × 10 −3 ± 0.5 × 10 −3 m in liver cells. [122] Therefore, the application of ATP as a trigger or a chemical fuel is of high relevance to developing responsive nanomedicine for cancer immunotherapy.…”

Section: High-level Atpmentioning

confidence: 88%

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

et al. 2021

View full text Add to dashboard Cite

The past decades have witnessed great progress in cancer immunotherapy, which has profoundly revolutionized oncology, whereas low patient response rates and potential immune-related adverse events remain major clinical challenges. With the advantages of controlled delivery and modular flexibility, cancer nanomedicine has offered opportunities to strengthen antitumor immune responses and to sensitize tumor to immunotherapy. Furthermore, tumor-microenvironment (TME)-responsive nanomedicine has been demonstrated to achieve specific and localized amplification of the immune response in tumor tissue in a safe and effective manner, increasing patient response rates to immunotherapy and reducing the immune-related side effects simultaneously. Here, the recent progress of TME-responsive nanomedicine for cancer immunotherapy is summarized, which responds to the signals in the TME, such as weak acidity, reductive environment, high-level reactive oxygen species, hypoxia, overexpressed enzymes, and high-level adenosine triphosphate. Moreover, the potential to combine nanomedicine-based therapy and immunotherapeutic strategies to overcome each step of the cancer-immunity cycle and to enhance antitumor effects is discussed. Finally, existing challenges and further perspectives in this rising field with the hope for improved development of clinical applications are discussed.

show abstract

Section: High-level Atpmentioning

confidence: 88%

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In tumor tissues, these active pathways promote glycolysis in hypoxia, promoting mitochondria to produce large amounts of ATP. The sharp different concentration of ATP contrast between extracellular (<0.4 mM) and intracellular (1–10 mM) is a characteristic of TME, and the use of ATP can be a practical way for regulating drug release [ 83 , 84 ]. In addition, tumor cells usually metabolize vigorously, and once there is a lack of energy, cell damage happens.…”

Section: Special Characteristics Of Tumor Microenvironmentmentioning

confidence: 99%

“…Besides the cell injury, the hypoxic-induced stress of TME is also a strong stimulus for ATP release [ 85 ]. The ATP concentration in TME is remarkably more than those in normal tissues (10–100 nM) [ 84 ]. Based on such a concentration difference, the ATP stimulating response system can be designed to ensure the drugs reach the tumor site more accurately.…”

Section: Special Characteristics Of Tumor Microenvironmentmentioning

confidence: 99%

Exploiting a New Approach to Destroy the Barrier of Tumor Microenvironment: Nano-Architecture Delivery Systems

Sun

Shi

et al. 2021

Molecules

View full text Add to dashboard Cite

Recent findings suggest that tumor microenvironment (TME) plays an important regulatory role in the occurrence, proliferation, and metastasis of tumors. Different from normal tissue, the condition around tumor significantly altered, including immune infiltration, compact extracellular matrix, new vasculatures, abundant enzyme, acidic pH value, and hypoxia. Increasingly, researchers focused on targeting TME to prevent tumor development and metastasis. With the development of nanotechnology and the deep research on the tumor environment, stimulation-responsive intelligent nanostructures designed based on TME have attracted much attention in the anti-tumor drug delivery system. TME-targeted nano therapeutics can regulate the distribution of drugs in the body, specifically increase the concentration of drugs in the tumor site, so as to enhance the efficacy and reduce adverse reactions, can utilize particular conditions of TME to improve the effect of tumor therapy. This paper summarizes the major components and characteristics of TME, discusses the principles and strategies of relevant nano-architectures targeting TME for the treatment and diagnosis systematically.

show abstract

“…Finally, Dox-GA subsequently targeted mitochondria to reduce the O2 level to maximize the efficacy of PDT. Adapted with permission from (Li et al, 2021) Frontiers in Bioengineering and Biotechnology | www.frontiersin.org June 2022 | Volume 10 | Article 916952 Sameiyan et al, 2021). Gu's group developed an ATP-responsive nanogel (Dox/NG) consisting of a DNA motif containing an ATP aptamer and its complementary strand with doxorubicin insertion, protamine, and a hyaluronic acid (HA)-crosslinked shell (Mo et al, 2014).…”

Section: Atp-responsive Ddsmentioning

confidence: 99%

Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy

Cong

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Spatially- and/or temporally-controlled drug release has always been the pursuit of drug delivery systems (DDSs) to achieve the ideal therapeutic effect. The abnormal pathophysiological characteristics of the tumor microenvironment, including acidosis, overexpression of special enzymes, hypoxia, and high levels of ROS, GSH, and ATP, offer the possibility for the design of stimulus-responsive DDSs for controlled drug release to realize more efficient drug delivery and anti-tumor activity. With the help of these stimulus signals, responsive DDSs can realize controlled drug release more precisely within the local tumor site and decrease the injected dose and systemic toxicity. This review first describes the major pathophysiological characteristics of the tumor microenvironment, and highlights the recent cutting-edge advances in DDSs responding to the tumor pathophysiological environment for cancer therapy. Finally, the challenges and future directions of bio-responsive DDSs are discussed.

show abstract

Aptamer-based ATP-responsive delivery systems for cancer diagnosis and treatment

Cited by 49 publications

References 113 publications

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

Exploiting a New Approach to Destroy the Barrier of Tumor Microenvironment: Nano-Architecture Delivery Systems

Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy

Contact Info

Product

Resources

About